SEC Form 4 · accession 0001179110-16-022870
RIGEL PHARMACEUTICALS INC · RIGL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan D Maynard
Officer — EVP & CFO
Period of report
Apr 4, 2016
Accepted (ET)
Apr 6, 2016 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001034842
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.59 | Apr 4, 2016 | A | 62,500 | A | — | Feb 27, 2024 | Common Stock | 62,500 | 62,500 | D |
| Employee Stock Option (right to buy)F2 | $2.14 | Apr 4, 2016 | A | 175,000 | A | — | Jan 26, 2025 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1On February 27, 2014, the reporting person was granted an option to purchase 62,500 shares of common stock. The option vests based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On April 4, 2016, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option.
- F2On January 26, 2015, the reporting person was granted an option to purchase 175,000 shares of common stock. The option vests based on the Compensation Committee's determination that one or more pre-established performance conditions had been achieved. On April 4, 2016, the Compensation Committee determined that the performance conditions had been achieved, resulting in full vesting of the option.